Read by QxMD icon Read

Journal of Headache and Pain

Doga Vuralli, Cenk Ayata, Hayrunnisa Bolay
Cognitive dysfunction has recently gained attention as a significant problem among migraine sufferers. All of the clinical studies show poor cognitive performance during migraine attacks, though, the interictal data are conflicting. Migraineurs show impaired cognitive function interictally in most of the clinic-based studies. Population-based studies did not reveal a difference in cognitive functions between migraineurs and controls. The specific cognitive domains involved are information processing speed, basic attention, executive functions, verbal and non-verbal memory and verbal skills...
November 15, 2018: Journal of Headache and Pain
Jishi Ye, Huang Ding, Juan Ren, Zhongyuan Xia
BACKGROUND: There has been tremendous change on neuropathic pain research in the past 20 years in China and around the world. We analyzed the global trend of neuropathic pain research and compared China's quantity and quality of neuropathic pain-related publications with other developed countries. METHODS: Using terms "neuropathic pain", we retrieved related publications from the Web of Science (WOS) database and PubMed database. From different aspects, such as the number of papers, total citations, average citations per item, H-index, research types, orientation, institutions, journals and funding, global neuropathic pain publications were classified and analyzed...
November 15, 2018: Journal of Headache and Pain
Chao-Hung Chen, Jau-Jiuan Sheu, Yi-Chun Lin, Herng-Ching Lin
BACKGROUND: Several studies examined headaches as a symptom of brain neoplasms. Nevertheless, very few studies attempted to specifically evaluate the role of headaches as a risk factor. This study aimed to investigate the risk of migraine occurrence in the preceding years among patients diagnosed with brain tumors and unaffected controls. METHODS: Data were obtained from the Taiwan National Health Insurance Research Database. In total, 11,325 adults with a first-time brain tumor diagnosis were included as cases, together with 11,325 unaffected matched controls...
November 15, 2018: Journal of Headache and Pain
Debora De Carlo, Irene Toldo, Agnese Maria Tamborino, Barbara Bolzonella, Maria Giuseppina Ledda, Lucia Margari, Vincenzo Raieli, Margherita Santucci, Vittorio Sciruicchio, Angelo Vecchio, Sergio Zanini, Stefano Sartori, Michela Gatta, Alberto Verrotti, Pier Antonio Battistella
BACKGROUND: This multicentric survey investigates the prevalence and characteristics of Airplane Headache in children affected by primary headaches. METHODS: Patients with symptoms of Airplane Headache were recruited from nine Italian Pediatric Headache Centres. Each patient was handed a structured questionnaire which met the ICHD-III criteria. RESULTS: Among 320 children suffering from primary headaches who had flights during their lifetime, 15 (4...
November 14, 2018: Journal of Headache and Pain
Éva Csépány, Marianna Tóth, Tamás Gyüre, Máté Magyar, György Bozsik, Dániel Bereczki, Gabriella Juhász, Csaba Ertsey
BACKGROUND: Despite its high prevalence, migraine remains underdiagnosed and undertreated. ID-Migraine is a short, self-administrated questionnaire, originally developed in English by Lipton et al. and later validated in several languages. Our goal was to validate the Hungarian version of the ID-Migraine Questionnaire. METHODS: Patients visiting two headache specialty services were enrolled. Diagnoses were made by headache specialists according to the ICHD-3beta diagnostic criteria...
November 12, 2018: Journal of Headache and Pain
Giuseppe Tringali, Diego Currò, Pierluigi Navarra
BACKGROUND: Perampanel is a novel antiepileptic drug acting via non-competitive antagonism on glutamatergic AMPA receptors, and the subsequent inhibition of ion calcium influx. Since it was recently postulated that the antagonists of glutamate receptors might play a role in the treatment of migraine, in this study we investigated the putative anti-migraine activity of perampanel in an in vitro animal model involving the static incubation of rat brainstem explants and the subsequent measurement of immune-reactive calcitonin gene-related peptide released into the incubation medium...
November 12, 2018: Journal of Headache and Pain
Casper Emil Christensen, Samaira Younis, Marie Deen, Sabrina Khan, Hashmat Ghanizada, Messoud Ashina
BACKGROUND: Migraine prevention with erenumab and migraine induction by calcitonin gene-related peptide (CGRP) both carry notable individual variance. We wanted to explore a possible association between individual efficacy of anti-CGRP treatment and susceptibility to migraine induction by CGRP. METHODS: Thirteen migraine patients, previously enrolled in erenumab anti-CGRP receptor monoclonal antibody trials, received CGRP in a double-blind, placebo-controlled, randomized cross-over design to investigate their susceptibility to migraine induction...
November 8, 2018: Journal of Headache and Pain
Giannapia Affaitati, Raffaele Costantini, Claudio Tana, Domenico Lapenna, Cosima Schiavone, Francesco Cipollone, Maria Adele Giamberardino
BACKGROUND: In migraine patients with cervical myofascial trigger points whose target areas coincide with migraine sites (M + cTrPs), TrP anesthetic injection reduces migraine symptoms, but the procedure often causes discomfort. This study evaluated if a topical TrP treatment with 3% nimesulide gel has similar efficacy as the injection but produces lesser discomfort with higher acceptability by the patients. METHODS: Retrospective analysis of medical charts of M + cTrPs patients in the period January 2012-December 2016 at a single Headache Center...
November 8, 2018: Journal of Headache and Pain
Daniyal J Jafree, Joanna M Zakrzewska, Saumya Bhatia, Carolina Venda Nova
BACKGROUND: Better tools are required for the earlier identification and management of orofacial pain with different aetiologies. The painDETECT questionnaire is a patient-completed screening tool with utility for identification of neuropathic pain in a range of contexts. 254 patients, referred from primary care for management of orofacial pain and attending a secondary care centre, were prospectively recruited, and completed the painDETECT prior to consultation. The aim of this study was to determine the accuracy of the painDETECT to detect neuropathic components of orofacial pain, when compared to a reference standard of clinical diagnosis by experienced physicians, in a cohort of hospital-based patients...
November 6, 2018: Journal of Headache and Pain
Xue-Ying Wang, Hui-Ru Zhou, Sha Wang, Chao-Yang Liu, Guang-Cheng Qin, Qing-Qing Fu, Ji-Ying Zhou, Li-Xue Chen
BACKGROUND: Although the mechanism of chronic migraine (CM) is unclear, it might be related to central sensitization and neuronal persistent hyperexcitability. The tyrosine phosphorylation of NR2B (NR2B-pTyr) reportedly contributes to the development of central sensitization and persistent pain in the spinal cord. Central sensitization is thought to be associated with an increase in synaptic efficiency, but the mechanism through which NR2B-pTyr regulates synaptic participation in CM-related central sensitization is unknown...
November 6, 2018: Journal of Headache and Pain
Paolo Martelletti, Piero Barbanti, Licia Grazzi, Giulia Pierangeli, Innocenzo Rainero, Pierangelo Geppetti, Anna Ambrosini, Paola Sarchielli, Cristina Tassorelli, Eric Liebler, Marina de Tommaso
BACKGROUND: Non-invasive vagus nerve stimulation (nVNS) has been shown to be practical, safe, and well tolerated for treating primary headache disorders. The recent multicenter, randomized, double-blind, sham-controlled PRESTO trial provided Class I evidence that for patients with episodic migraine, nVNS significantly increases the probability of having mild pain or being pain-free 2 h post stimulation. We report additional pre-defined secondary and other end points from PRESTO that demonstrate the consistency and durability of nVNS efficacy across a broad range of outcomes...
November 1, 2018: Journal of Headache and Pain
Caroline Ran, Carmen Fourier, Margret Zinnegger, Anna Steinberg, Christina Sjöstrand, Elisabet Waldenlind, Andrea Carmine Belin
BACKGROUND: Cluster headache is a severe headache disorder with unknown aetiology. The pathophysiology and symptoms present certain common features with migraine. Specifically, activation of the trigeminal vascular system seems to be involved in both disorders, which is hypothesized to result in neurogenic inflammation and vasodilation of the cerebral vessels. In addition, genetic factors have been implicated in both migraine and cluster headache. OBJECTIVE: In order to determine whether or not migraine and cluster headache share genetic risk factors, we screened two genetic variants known to increase the risk of migraine in Sweden in a Swedish cluster headache case-control study population...
November 1, 2018: Journal of Headache and Pain
Steffen Naegel, Josephine Biermann, Nina Theysohn, Christoph Kleinschnitz, Hans-Christoph Diener, Zaza Katsarava, Mark Obermann, Dagny Holle
BACKGROUND: To enrich the hitherto insufficient understanding regarding the mechanisms of action of transcranial direct current stimulation (tDCS) in pain disorders, we investigated its modulating effects on cerebral pain processing using functional magnetic resonance imaging (fMRI). METHODS: Thirteen right-handed healthy participants received 20 min of 1.5 mA tDCS applied over the primary motor cortex thrice and under three different stimulation pattern (1.anodal-tDCS, 2...
October 24, 2018: Journal of Headache and Pain
Licia Grazzi, Cristina Tassorelli, Marina de Tommaso, Giulia Pierangeli, Paolo Martelletti, Innocenzo Rainero, Pierangelo Geppetti, Anna Ambrosini, Paola Sarchielli, Eric Liebler, Piero Barbanti
BACKGROUND: The PRESTO study of non-invasive vagus nerve stimulation (nVNS; gammaCore®) featured key primary and secondary end points recommended by the International Headache Society to provide Class I evidence that for patients with an episodic migraine, nVNS significantly increases the probability of having mild pain or being pain-free 2 h post stimulation. Here, we examined additional data from PRESTO to provide further insights into the practical utility of nVNS by evaluating its ability to consistently deliver clinically meaningful improvements in pain intensity while reducing the need for rescue medication...
October 19, 2018: Journal of Headache and Pain
Kjersti Grøtta Vetvik, E Anne MacGregor, Christofer Lundqvist, Michael Bjørn Russell
BACKGROUND: Menstrual migraine (MM) and premenstrual syndrome (PMS) are two conditions linked to specific phases of the menstrual cycle. The exact pathophysiological mechanisms are not fully understood, but both conditions are hypothesized to be triggered by female sex hormones. Co-occurrence of MM and PMS is controversial. The objective of this population-based study was to compare self-assessed symptoms of PMS in female migraineurs with and without MM. A total of 237 women from the general population who self-reported migraine in at least50% of their menstruations in a screening questionnaire were invited to a clinical interview and diagnosed by a neurologist according to the International Classification of Headache Disorders II (ICHD II), including the appendix criteria for MM...
October 17, 2018: Journal of Headache and Pain
Adeladlew Kassie Netere, Daniel Asfaw Erku, Ashenafi Kibret Sendekie, Eyob Alemayehu Gebreyohannes, Niguse Yigzaw Muluneh, Sewunet Admasu Belachew
BACKGROUND: Headache is one of the most common disabling medical condition affecting over 40% of adults globally. Many patients with headache prefer to alleviate their symptom with a range of over-the-counter analgesics that are available in community medicine retail outlets (CMROs). However, data regarding how community pharmacists respond to headache presentation and their analgesic dispensing behaviors in Ethiopia is scarce. The present study aimed to assess the self-reported and actual practice of community pharmacists toward management of a headache in Gondar town, Ethiopia...
October 16, 2018: Journal of Headache and Pain
Jing Wang, Weihao Xu, Shasha Sun, Shengyuan Yu, Li Fan
BACKGROUND: Until now, headache disorders have not been established as a risk factor for dementia. The aim of this study was to determine whether headache was associated with an increased risk of dementia. METHODS: We systematically searched electronic databases, including PubMed, Embase, and Web of Science, for studies investigating the association between headache and dementia. We then conducted a meta-analysis to determine a pooled-effect estimate of the association...
October 11, 2018: Journal of Headache and Pain
Thijs H T Dirkx, Danielle Y P Haane, Peter J Koehler
BACKGROUND: Cluster headache attacks can, in many patients, be successfully treated with oxygen via a non-rebreather mask. In previous studies oxygen at flow rates of both 7 L/min and 12 L/min was shown to be effective. The aim of this study was to compare the effect of 100% oxygen at different flow rates for the treatment of cluster headache attacks. METHODS: In a double-blind, randomized, crossover study, oxygen naïve cluster headache patients, treated attacks with oxygen at 7 and 12 L/min...
October 10, 2018: Journal of Headache and Pain
Jan Hoffmann, Susan P Mollan, Koen Paemeleire, Christian Lampl, Rigmor H Jensen, Alexandra J Sinclair
BACKGROUND: Idiopathic Intracranial Hypertension (IIH) is characterized by an elevation of intracranial pressure (ICP no identifiable cause. The aetiology remains largely unknown, however observations made in a number of recent clinical studies are increasing the understanding of the disease and now provide the basis for evidence-based treatment strategies. METHODS: The Embase, CDSR, CENTRAL, DARE and MEDLINE databases were searched up to 1st June 2018. We analyzed randomized controlled trials and systematic reviews that investigate IIH...
October 8, 2018: Journal of Headache and Pain
Todd Schwedt, Uwe Reuter, Stewart Tepper, Messoud Ashina, David Kudrow, Gregor Broessner, Guy P Boudreau, Peter McAllister, Thuy Vu, Feng Zhang, Sunfa Cheng, Hernan Picard, Shihua Wen, Joseph Kahn, Jan Klatt, Daniel Mikol
BACKGROUND: Subcutaneous erenumab reduced monthly migraine days and increased the likelihood of achieving a ≥ 50% reduction at all monthly assessment points tested in 2 pivotal trials in episodic migraine (EM) and chronic migraine (CM). Early efficacy of migraine preventive medications is an important treatment characteristic to patients. Delays in achievement of efficacy can result in failed adherence. The objective of these post-hoc analyses were to evaluate efficacy in the first 4 weeks after initial subcutaneous administration of erenumab 70 mg, erenumab 140 mg, or placebo...
October 1, 2018: Journal of Headache and Pain
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"